



2020, №1  
ISSN 2181-466X

# *Doktor Axborotnomasi*





**Учредитель:**  
САМАРКАНДСКИЙ  
ГОСУДАРСТВЕННЫЙ  
МЕДИЦИНСКИЙ ИНСТИТУТ

**ЎЗБЕКИСТОН РЕСПУБЛИКАСИ  
СОҒЛИКНИ САҚЛАШ ВАЗИРЛИГИ**

\*\*\*\*\*

**МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ  
РЕСПУБЛИКИ УЗБЕКИСТАН**

**ДОКТОР АХБОРОТНОМАСИ  
ВЕСТНИК ВРАЧА  
DOCTOR'S HERALD**

Журнал входит в перечень научных журналов  
и изданий, рекомендованных ВАК при  
Кабинете Министров Республики Узбекистан  
при защите докторских диссертаций

**UCH OYLIK**

**ILMIY-AMALIY JURNAL**

1997 yilda t.f.d. J. A. Ahtamov  
tomonidan tashkil etilgan

**ЕЖЕКВАРТАЛЬНЫЙ  
НАУЧНО-ПРАКТИЧЕСКИЙ  
ЖУРНАЛ**

Основан в 1997 году  
д.м.н. Дж. А. Ахтамовым

**QUARTERLY SCIENTIFIC  
AND PRACTICAL JOURNAL**

Founded in 1997  
by ph.d. J. A. Akhtamov

**Адрес редакции:**

Республика Узбекистан, 140100, г.Самарканд,  
ул.Амира Темура, 18.  
Тел.: +998 97 9291009

**e-mail:** [vestnikvracha.vv@gmail.com](mailto:vestnikvracha.vv@gmail.com)

**Дополнительная информация:**  
[vestnikvracha.uz](http://vestnikvracha.uz)

Журнал зарегистрирован в  
Самаркандском областном  
управлении печати и информации  
01 июля 2016 года  
(регистрационный № 09-35).

Сдано в набор 23.03.2020.

Подписано в печать 30.03.2020.

Формат А 4. Гарнитура Times New Roman.

Объем 19,75 усл. п.л. Тираж 100 экз.

Отпечатано в типографии СамГосМИ.

Заказ № 20 (от 16.03.2020).

**№ 1 (93)  
2020 yil**

<http://doi.org/10.38095/2181-466X-2020931>

**РЕДАКЦИОННАЯ КОЛЛЕГИЯ:**

Главный редактор:

Ж. А. Ризаев

Зам. главного редактора:

Б.Б. Негмаджанов

Ответственный секретарь:

В.О. Ким

А.А. Абдукадыров, Т.У. Арипова,  
Ю.М. Ахмедов, Ш.Х. Зиядуллаев,  
Ш.Б. Иргашев, З.Б. Курбаниязов,  
Г.У. Лутфуллаев, Р.Ю. Рузибаев,  
А.М. Хайдаров, Г.А. Хакимов,  
Н.М. Шавази, А.М. Шамсиев,  
Р.Х. Шарипов, К.Э. Шомуродов,  
А.А. Юсупов

**РЕДАКЦИОННЫЙ СОВЕТ:**

А.А. Абдусаломов, Л.М. Абдуллаева,  
Л.Р. Агабабян, А.А. Ахмедов,  
Ж.А. Атакулов, А.Т. Джурабекова,  
З.С. Камалов, В.И. Лим,  
С.Э. Мамараджабов, С.Н. Пардаев,  
А.В. Полевщиков, Г.У. Самиева,  
А.Т. Сафаров, Э.С. Тоиров,  
Х.Т. Хамраев, Т.Р. Хегай,  
А.Ш. Шодиев, Н.А. Ярмухамедова

- |  |  |  |
|--|--|--|
| <p><b>Г. Ю. Тураева</b><br/>СОСТОЯНИЕ ГЕМОДИНАМИЧЕСКИХ И<br/>МОРФОЛОГИЧЕСКИХ ПАРАЛЛЕЛЕЙ<br/>У ЖЕНЩИН С ПРЕЖДЕВРЕМЕННЫМИ<br/>РОДАМИ В АНАМНЕЗЕ</p> <p><b>Б. Х. Хамидов, Ф. М. Хуррамов,<br/>Н. Н. Назаров, М. Х. Назирова</b><br/>КОМПЛЕКСНАЯ ДИАГНОСТИКА<br/>И ЛЕЧЕНИЕ НЕДЕРЖАНИЯ<br/>МОЧИ У ДЕТЕЙ</p> <p><b>Н. Р. Хамидова, М. Н. Негматуллаева,<br/>Д. И. Туксанова, Ф. К. Ахмедов</b><br/>РОЛЬ ПОКАЗАТЕЛЕЙ СИСТЕМЫ<br/>ГЕМОСТАЗА В ПРОГНОЗИРОВАНИИ<br/>АКУШЕРСКИХ КРОВОТЕЧЕНИЙ</p> <p><b>Н. Ж. Хушвакова, Г. Б. Давронова</b><br/>ОРТТИРИЛГАН НЕЙРОСЕНСОР<br/>ҚАТТИҚҚЎЛОҚЛИКНИ ДАВОЛАШ<br/>УСУЛЛАРИНИ ТАКОМИЛЛАШТИРИШ</p> <p><b>А. М. Шамсиев, С. С. Зайниев, Н. К. Алиева</b><br/>КЛИНИКО-МОРФОЛОГИЧЕСКАЯ<br/>ХАРАКТЕРИСТИКА ХРОНИЧЕСКОГО<br/>РЕЦИДИВИРУЮЩЕГО ГЕМАТОГЕННОГО<br/>ОСТЕОМИЕЛИТА</p> <p><b>Р. Х. Шарипов, Н. А. Расулова,<br/>М. М. Ахмедова, А. С. Расулов, Л. Т. Ирбутаева</b><br/>ЭФФЕКТИВНОСТЬ ОКСИБРАЛА<br/>ПРИ КОРРЕКЦИИ НАРУШЕНИЙ<br/>ЛИПИДНОЙ ПЕРОКСИДАЦИИ У<br/>ДЕТЕЙ С ПОСЛЕДСТВИЯМИ<br/>ПЕРИНАТАЛЬНОГО ПОВРЕЖДЕНИЯ<br/>НЕРВНОЙ СИСТЕМЫ</p> <p><b>И. Б. Шукуров, Ч. К. Хайруллаев,<br/>М. Т. Гуломова, Ф. Ф. Умуоров</b><br/>ВЛИЯНИЕ ВИТАМИНА Е НА<br/>БИОХИМИЧЕСКИЕ ПАРАМЕТРЫ В<br/>ЭКСПЕРИМЕНТЕ</p> <p><b>А. С. Юлдашева, Г. М. Ахмаджонова</b><br/>ПРОБЛЕМЫ АЦИКЛИЧЕСКОГО<br/>МАТОЧНОГО КРОВОТЕЧЕНИЯ<br/>В ПЕРИОД ПЕРИМЕНОПАУЗЫ</p> | <p>80</p> <p>83</p> <p>86</p> <p>89</p> <p>93</p> <p>100</p> <p>103</p> <p>106</p> | <p><b>G. Yu. Turaeva</b><br/>CONDITION HEMODYNAMIC AND<br/>MORPHOLOGICAL PARALLELS<br/>WOMEN WITH PREMATURE GENUS<br/>IN ANAMNESIS</p> <p><b>B. Kh. Khamidov, F. M. Khurramov,<br/>N. N. Nazarov, M. Kh. Nazirova</b><br/>COMPREHENSIVE DIAGNOSIS<br/>AND TREATMENT OF URINARY<br/>INCONTINENCE IN CHILDREN</p> <p><b>N. R. Khamidova, M. N. Negmatullaeva,<br/>D. I. Tuksanova, F. K. Akhmedov</b><br/>THE ROLE OF HEMOSTATIC SYSTEM<br/>INDICATORS IN PREDICTING OBSTETRIC<br/>BLEEDING</p> <p><b>N. J. Khushvakova, G. B. Davronova</b><br/>OPTIMIZATION TREATMENT<br/>METHODS OF ACQUIRED<br/>NEUROSENSOR HEARING AID</p> <p><b>A. M. Shamsiev, S. S. Zainiev, N. K. Alieva</b><br/>CLINICAL AND MORPHOLOGICAL<br/>CHARACTERISTICS OF CHRONIC<br/>RECURRENT HEMATOGENOUS<br/>OSTEOMYELITIS</p> <p><b>R.Kh. Sharipov, N.A. Rasulova,<br/>M.M. Axmedova, A.S. Rasulov, L.T. Irbutaeva</b><br/>THE EFFECTIVENESS OF OXYBRAL IN<br/>THE CORRECTION OF LIPID<br/>PEROXIDATION DISORDERS IN<br/>CHILDREN WITH THE CONSEQUENCES<br/>OF PERINATAL DAMAGE TO THE<br/>NERVOUS SYSTEM</p> <p><b>I. B. Shukurov, Ch. K. Khayrullayev,<br/>M. T. Gulomova, F. F. Umurov</b><br/>THE EFFECT OF VITAMIN E ON THE<br/>BIOCHEMICAL PARAMETERS IN THE<br/>EXPERIMENT</p> <p><b>A. S. Yuldasheva, G. M. Akhmadzhonova</b><br/>PROBLEMS AT PERIMENOPAUSE<br/>IN ACYCLIC UTERINE<br/>BLEEDING</p> |
|--|--|--|

### ОБЗОР ЛИТЕРАТУРЫ

- Л. С. Абдуллаева, М. Х. Каттаходжаева, А. Т. Сафаров, С. С. Гайибов**  
ПРОГНОЗИРОВАНИЕ И ПРОФИЛАКТИКА  
АКУШЕРСКИХ И ПЕРИНАТАЛЬНЫХ  
ОСЛОЖНЕНИЙ ПРИ МНОГОПЛОДНОЙ  
БЕРЕМЕННОСТИ
- Д. Т. Каюмова**  
АЛЬТЕРНАТИВНЫЕ ВАРИАНТЫ  
ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ

### LITERATURE REVIEW

- 109 **L. S. Abdullayeva, M. X. Kattaxodjayeva, A. T. Safarov, S. S. Gayibov**  
PROGNOSIS AND PREVENTION OF  
OBSTETRIC AND PERINATAL  
COMPLICATIONS IN MULTIPLE  
PREGNANCIES
- 113 **D. T. Kayumova**  
ALTERNATIVE VARIANTS OF  
THE PREVENTIVE MAINTENANCE AND



**THE ROLE OF HEMOSTATIC SYSTEM INDICATORS  
IN PREDICTING OBSTETRIC BLEEDING****N. R. Khamidova, M. N. Negmatullaeva, D. I. Tuksanova, F. K. Akhmedov**  
Bukhara state medical institute, Bukhara, Uzbekistan**Key words:** physiological pregnancy, D-dimer, fibrinolysis, hemostasiologic.**Таянч сўзлар:** физиологик ҳомиладорлик, Д-димер, фибринолиз, гемостазиологик.**Ключевые слова:** физиологическая беременность, D-димер, фибринолиз, гемостазиологический.

The purpose of the study: to evaluate the state of hem coagulation with its physiological course for predicting the risk of obstetric hemorrhage in terms of trimesters of pregnancy in its dynamics. Surveyed 65 women with physiological pregnancy. Of these, 30 women (group II) have risk factors; smoking patients during this pregnancy, overweight, taking oral contraceptives with the abolition of less than or 3 months before pregnancy. 35- Women without risk factors with a normal pregnancy. Clinical and hemostasiologic studies were performed for periods of 10–12, 22–24, and 35–36 weeks of gestation. During gestation, there was an increase in spontaneous platelets, an increase in fibrinogen level, D-dimer, and a slowdown in fibrinolysis.

**АКУШЕРЛИК ҚОН КЕТИШИНИ БАШОРАТЛАШДА ГЕМОСТАЗ  
КЎРСАТКИЧЛАРИНИНГ АҲАМИЯТИ****Н. Р. Хамидова, М. Н. Негматуллаева, Д. И. Туксанова, Ф. К. Ахмедов**

Бухоро давлат тиббиёт институти, Бухоро, Ўзбекистон

Тадқиқот мақсади: ҳомиладорлиги физиологик кечаётган аёлларда динамикада акушерлик қон кетиши хавфини башорат қилиш, учун қон ивишининг ҳолатини баҳолашдан иборат. Ҳомиладорлиги физиологик кечаётган 65 нафар аёл ўртасида текширув ўтказилди. Улардан 30 нафар аёл (II гуруҳ) хавф омилларига эга; ҳомиладорлик пайтида чекадиган, ортиқча вазнга эга бўлган, ҳомиладорликдан 3 ой олдин ёки ундан 3 ой олдин контрацептив воситаларни қабул қилган аёллар. 35 - нафар эса хавф омиллари бўлмаган ҳомиладор аёллар олинди. Клиник ва гемостазиологик тадқиқотлар ҳомиладорликнинг 10–12, 22–24 ва 35–36 ҳафталаарида ўтказилди. Ҳомиладорлик пайтида ўз-ўзидан пайдо бўлган тромбоцитларнинг кўпайиши, фибриноген даражасининг ошиши, Д-димер ва фибринолизнинг секинлашиши кузатилди.

**РОЛЬ ПОКАЗАТЕЛЕЙ СИСТЕМЫ ГЕМОСТАЗА В ПРОГНОЗИРОВАНИИ  
АКУШЕРСКИХ КРОВОТЕЧЕНИЙ****Н. Р. Хамидова, М. Н. Негматуллаева, Д. И. Туксанова, Ф. К. Ахмедов**

Бухарский государственный медицинский институт, Бухара, Узбекистан

Цель исследования: оценить состояние гемокоагуляции с ее физиологическим течением для прогнозирования риска возникновения акушерских кровотечений в условиях триместра беременности в его динамике. Обследовано 65 женщин с физиологической беременностью. Из них 30 женщин (группа II) имеют факторы риска; Курящие пациенты во время этой беременности имеют избыточный вес, принимают оральные контрацептивы с отменой менее чем за 3 месяца до беременности. 35- Женщины без факторов риска с нормальной беременностью. Клинические и гемостазиологические исследования проводились в течение 10–12, 22–24 и 35–36 недель беременности. Во время беременности наблюдалось увеличение спонтанных тромбоцитов, повышение уровня фибриногена, D-димера и замедление фибринолиза.

Obstetric hemorrhages are the leading cause of maternal mortality in most countries of the world, including our Republic of Uzbekistan. The frequency of obstetric bleeding with blood loss of more than 1000 ml is from 2 to 8% in relation to the total number of births. Massive bleeding due to a combination of several causes and almost always accompanied by gross violations of the hem coagulation system [1,3,6].

Bleeding as the cause of maternal and prenatal mortality during pregnancy, in childbirth and the postpartum period continues to be one of the urgent problems of modern obstetrics, being in 20–28% of cases the only cause of deaths for the mother and fetus [4,5].

Massive bleeding may be due to a number of reasons and more often their combination. A practical doctor is not always in the state of the variety of them to distinguish leading and implement the most rational prevention and therapy. The difficulty of real and differentiated prevention of massive blood loss is due to several factors, one of the main factors being the presence of physi-

ological hyper coagulation, as the “pregnancy rate” [2,9,10].

However, the prognostic criteria for hemostatic system impairment resulting in massive obstetric bleeding remain deeply unexplored. Changes in the hemostatic system of a pregnant woman are physiological and are associated with the appearance of the uteroplacental circulation. This process is due to various factors and is an adaptive response of the pregnant woman's body to compensation of costs due to the development of the fetus and possible blood loss during childbirth.

An important indicator to characterize the degree of hemostasis activation is the level of D-dimer. With fibrin cleavage, the final products are formed D-dimers. In healthy people, the concentration of D-dimer does not exceed 500 mg / ml FEV (units equivalent of fibrinogen). An excess of D-dimer indicates activation of fibrinolysis and an increase in the formation of thrombin [7,8,10].

During normal pregnancy, the level of D-dimer in the blood plasma gradually increases several times, reaching its peak by the first day of the postpartum period.

Excessive increase in D-dimer is considered evidence of the unfavorable course of pregnancy and labor associated with impairment in the hemostasis system, including the development of the risk of massive obstetric hemorrhage [8,9].

**The study's purpose:** to evaluate the state of hemocoagulation with its physiological course for predicting the risk of obstetric hemorrhage in terms of trimesters of pregnancy in its dynamics.

**Material and methods.** The study involved 65 women with physiological pregnancy. Of these, 30 women (group II) have risk factors; smoking patients during this pregnancy, overweight, taking oral contraceptives with the abolition of less than or 3 months before pregnancy. 35 - Women without risk factors with a normal pregnancy. Clinical and hemostasiologic studies were performed for periods of 10–12, 22–24, and 35–36 weeks of gestation. Clinical examination included analysis of complaints, history taking, physical examination, analysis of medical records. Blood for hemostasiological research was taken in the morning, on an empty stomach, from the cubital vein, using a needle with a wide lumen. The study was carried out for 2 hours from the moment the plasma was obtained on the “Biologist 2A-230-2” apparatus. Coagulation studies were performed using the “Technology – Standard” reagents on a Diamed-CD-4 semi-automatic coagulometer. Investigated activated plasma recalcification time (APR), activated partial prothromboplastin time (APTT), prothrombin time (PT), fibrinogen level. Statistical processing of the results was carried out using Student's criterion using the Statgraf and Microsoft Excel versions of the Windows software package.

**Results and discussion.** According to the inclusion criterion, 65 women were examined. The average age of the patient is 25 (22-30) years. Of these, 30 had the first birth, 35 - repeated. None of the patients before the survey did not receive anti-thrombotic therapy. The dynamics of hemostasis are presented in the table below.

When analyzing the results obtained in the table it should be noted that, APR, APTT, PT did not have dynamic static differences in trimesters. At the same time, an increase in PV by the end of pregnancy turned out to be statically significant compared with rates in the first and second trimesters. Since this test reflects the total antithrombin plasma activity, it is possible that the increase is due to an increase in the level of paracoagulation products, which have an anticoagulant effect.

When analyzing the number of platelets, we found no statistical differences with a slight decrease in mean values in the third trimester, which can be explained by both relative hemodilution and partial physiological consumption of platelets in the uteroplacental circulation.

It is noteworthy that there is an increase in the level of fibrinogen during pregnancy, which is 39.4% out of the normal range by the end of pregnancy compared with the first trimester. In parallel with hyperfibrinogenemia, there was a threefold increase in the content of D-dimer, respectively.

A comparative analysis of these parameters in the studied patients of groups I and II revealed a 3.7% increase in the number of platelets, ABP decreased by 3.8%, APTT decreased by 3.6%, PT

Table 1.

**Comparative indicators of hemostasis physiological course of pregnancy and in pregnant women at risk.**

Indicator	Trimester					
	I		II		III	
	I group (n=30)	II group (n=35)	I group (n=30)	II group (n=35)	I group (n=30)	II group (n=35)
Platelet count, 10 <sup>9</sup> /L	235±36	230±34	225±39	220±30	218±30	213±25
Spontaneous platelet aggregation, %	0.17±0.13	0.16±0.15**	0.35±0.15**	0.40±0.17**	0.34±0.14**	0.30±0.12**
APR (activated plasma recalcification time), s	56.1±5.1	55.1±4.9	57.6±5.4	58.5±5.1	56.9±5.3	54.8±5.4
APTT (activated partial thromboplastin time), s	33.8±2.6	33.6±2.8	33.3±3.0	33.1±2.9	33.3±2.8	32.1±2.9
Fibrinogen, g/l	3.8±0.6	4.1±0.5	4.2±0.5*	4.8±0.4**	5.3±1.5**	5.8±1.6
Prothrombin time, s	15.5±0.9	15.9±0.8	15.7±1.2	16.1±1.1	16.1±1.8***	17±1.6***
D-dimer, mg/ml	115±58.6	125±60.2	276.8±5.1*	301±1,2	469±77.7	540±80.5***

Note: Significance of differences ( $P < 0.05$ ) when comparing indicators: \* in I and II trimesters, \*\* - in I and III trimesters \*\*\* - in II and III trimesters.

increased by 5.6%. Indicators of D-dimers increased by 15.1% in the 3rd trimester in pregnant women with an existing risk group (Group II).

Thus, indicators of fibrinogen, D-dimer and PV can be early markers of changes in the hemostasis system in patients with risk factors even during physiological pregnancy, and they can be included in the group of pregnant women with a high risk of bleeding during childbirth. In order to prevent the expected risks that exist, it is necessary to address the issues of prenatal hospitalization, which require medical correction of hemostasis system parameters, in order to achieve a successful outcome of labor for the mother.

**References:**

1. Bertina R.M. Molecular risk factor for thrombosis // *Thrombosis and Haemostasis J.* 2013. № 2 (82). P.601-610.
2. Brenner B. Hemostatic changes in pregnancy // *Thrombosis Research.* P. 2014. Vol. 114. P. 409-414.
3. Halligan A., Bonnar J., Sheppard B., et al. Haemostatic, fibrinolytic and endothelial variables in normal pregnancy // *Br. J. Obstet. Gynecol.* 2014. № 6 (101). P. 488-492.
4. Kulikov, A.V. Emergency protocol for bleeding in obstetrics / A.V. Kulikov, S.V. Martirosyan, T.A. Obo-Skalova. - Ekaterinburg, 2010. - 28 p.
5. Modern technologies for the treatment of obstetric hemorrhages / V. E. Radzinsky [and others] // *Farmateka - 2010.* - № 1. - P. 12-16.
6. Olson JD. D-dimer: An Overview of Hemostasis and Fibrinolysis, Assays, and Clinical Applications. *Advances in Clinical Chemistry.* 2015;69:2-46. doi:10.1016/bs.acc.2014.12.001.
7. Opportunities for the prevention of massive blood loss in the postpartum period / V. A. Novikova [and others] // *Proceedings of the XIII All-Russian Scientific Forum "Mother and Child" September 25-28, 2012;* edited by G. T. Sukhikh. - M., 2012. - P. 124-125.
8. O’Riordan M.N., Higgins J.R. Haemostasis in normal and abnormal pregnancy // *Best Pract Res Clin Obstet Gynaecol.* 2013. № 3 (17). P. 385-396.
9. Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V and Paolo Prandoni. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. *Blood.* 2014;124(2):196-203. doi:10.1182/blood-2014-01-548065.
10. Prevention of massive bleeding in obstetric practice / V.L. Silyava [and others] // *Med. journals - 2012.* - № 1. - p. 77-81.
11. Schouten HJ, Geersing GJ, Koek HL, A Zuithoff N, Janssen K, Douma RA, van Delden JM, Moons K, Reitsma JB. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. *BMJ.* 2013;346:f2492. doi:10.1136/bmj.f2492.